Alzheimer’s disease is a devastating condition that disproportionately affects women, who make up roughly two-thirds of all patients. For decades, researchers and patients have debated whether menopausal hormone therapy helps or hurts cognitive health. Now, a Stanford University study offers new evidence linking estrogen-only hormone therapy to substantially lower levels of Alzheimer’s disease pathology. The findings could help researchers better understand the relationship between menopause, estrogen loss and neurodegeneration, although experts caution that the results are not proof that hormone therapy prevents Alzheimer’s.
What Happened
Researchers at Stanford Medicine analyzed health records from 21,462 women aged 50 and older using data from two major national databases: the National Alzheimer’s Coordinating Center and the Alzheimer’s Disease Neuroimaging Initiative.
The researchers examined clinical diagnoses, brain imaging, biomarker information and, when available, postmortem brain autopsy findings. That allowed the team to compare women who had used estrogen-only hormone therapy with women who had not.
The postmortem analysis was particularly important because researchers could directly examine physical characteristics associated with Alzheimer’s disease, including amyloid plaques and tau tangles.
The study found that women who had used estrogen-only hormone therapy had 35% lower odds of showing increased Alzheimer’s pathology in their brains after death compared with women who had not used the therapy.
Researchers also found that women who had used estrogen-only therapy had a 39% lower likelihood of receiving a clinical dementia diagnosis during their lifetime.
The researchers reported that women receiving estrogen-only therapy also had lower levels of amyloid-related biomarkers in blood and cerebrospinal fluid.
The apparent benefit was strongest among women who began hormone therapy earlier in menopause, according to the study.
Importantly, the findings applied specifically to estrogen-only therapy, rather than hormone treatment combining estrogen and progesterone.
Estrogen-only therapy is generally prescribed to women who have undergone a hysterectomy. Women who still have a uterus are typically prescribed progesterone alongside estrogen because taking estrogen alone can increase the risk of endometrial cancer.
Key Facts and Numbers
- 35%: Lower odds of increased Alzheimer’s-related brain pathology among women who used estrogen-only therapy.
- 39%: Lower likelihood of a clinical dementia diagnosis among women who used estrogen-only therapy.
- 21,462: Women included in the Stanford-led analysis.
- Two-thirds: Approximate share of Alzheimer’s patients who are women.
- Estrogen-only therapy: The specific hormone treatment associated with the lower levels of Alzheimer’s pathology in the study.
- Early treatment: The association appeared strongest among women who began therapy earlier in menopause.
Why It Matters
Women are approximately twice as likely as men to develop Alzheimer’s disease, and researchers have increasingly investigated whether hormonal changes associated with menopause contribute to that difference.
Estrogen has been shown to have effects on inflammation, brain signaling and other biological processes that could potentially influence neurodegeneration. When estrogen levels fall sharply during menopause, researchers have questioned whether that hormonal change could contribute to increased vulnerability later in life.
The Stanford findings add another piece to that puzzle.
The study's use of brain autopsy data is also significant. Rather than relying exclusively on memory tests or a clinical diagnosis, researchers were able to examine actual neurological changes associated with Alzheimer’s disease.
That distinction matters because someone can have Alzheimer's-related pathology in the brain without having received a formal dementia diagnosis during life.
The findings also come more than two decades after the Women's Health Initiative dramatically changed perceptions of hormone replacement therapy.
In 2002, results involving combined estrogen-and-progestin therapy raised concerns about dementia, breast cancer, heart disease and other health risks. Hormone therapy prescriptions subsequently declined sharply, and many women and physicians became reluctant to use the treatment.
The new research does not erase those concerns, but it may help scientists distinguish between different forms of hormone therapy and identify whether the timing of treatment matters.
What Researchers Are Saying
The Stanford researchers emphasized that the results should be interpreted within the limits of the study design.
The study's findings suggest an association between estrogen-only therapy and lower Alzheimer’s-related pathology, but they do not establish that estrogen therapy itself caused the reduction.
Researchers are particularly interested in the possibility that timing may be critical.
Women who begin hormone therapy close to the beginning of menopause may respond differently from women who begin treatment many years later. This idea, sometimes described as a “critical window,” is one of the major questions researchers are now investigating.
The researchers also noted that the results should not be interpreted as a recommendation for women to begin hormone therapy solely as a way to prevent Alzheimer’s disease.
The Earlier Hormone Therapy Debate
The history of hormone therapy makes the findings particularly complicated.
For years, hormone replacement therapy was widely used to treat menopausal symptoms. After the Women's Health Initiative results were released, however, concerns about long-term risks changed prescribing practices.
Those earlier findings primarily involved combined hormone therapy, meaning estrogen together with progestin.
The Stanford research raises the possibility that estrogen-only therapy may have a different relationship with brain health.
That distinction is important because estrogen-only therapy is not appropriate for everyone. Women who have an intact uterus generally need a progestogen when using systemic estrogen to protect against endometrial cancer.
As a result, the findings cannot simply be applied to all women considering menopausal hormone therapy.
A Skeptical View
A major limitation is that the Stanford research is observational, meaning researchers examined existing health records rather than randomly assigning women to receive estrogen therapy or a placebo. That makes it impossible to rule out other explanations for the findings. Women who used estrogen-only therapy may have differed from nonusers in healthcare access, socioeconomic factors, overall health, medical supervision, lifestyle or other characteristics that could influence dementia risk. The 35% and 39% figures therefore should not be interpreted as proof that estrogen therapy prevents Alzheimer’s disease. Randomized clinical trials would provide much stronger evidence about whether the hormone itself is responsible for the apparent protection.
What Happens Next
Researchers are expected to continue investigating whether estrogen's timing, dosage and delivery method influence neurological health.
Future studies could examine whether modern forms of hormone therapy, including transdermal patches and gels, produce similar results to oral estrogen treatments.
Another major question is whether women who require combined estrogen-and-progesterone therapy could experience comparable neurological effects.
Randomized clinical trials will ultimately be needed to determine whether hormone therapy can actually prevent or delay Alzheimer’s disease rather than simply being associated with lower disease markers.
For now, the findings are unlikely to change clinical recommendations on their own.
Doctors generally do not recommend menopausal hormone therapy specifically for the prevention of dementia. Instead, decisions about hormone therapy are made based on an individual's symptoms, age, medical history, risks and treatment goals.
What We Still Don't Know
- Does combined estrogen-and-progesterone therapy provide similar protection against Alzheimer’s pathology?
- How much does the age at which hormone therapy begins affect potential neurological benefits?
- Do estrogen patches and gels provide the same potential benefits as oral estrogen?
- What biological mechanisms could explain estrogen’s apparent relationship with amyloid and tau?
- Could hormone therapy delay the onset of cognitive decline rather than prevent Alzheimer’s entirely?
- Would randomized clinical trials confirm the protective association observed in this study?
- How should the potential brain benefits be weighed against the known risks of hormone therapy for individual patients?
Source Note
This story draws on reporting from Fox News.